Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 58, Issue 11, Pages 6993-6995Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.04035-14
Keywords
-
Categories
Funding
- Pfizer
- Astellas Pharma US
- Gilead Sciences, Inc.
- Merck Co., Inc.
Ask authors/readers for more resources
We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.01) without clinically relevant hepatotoxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
